ESLAEstrella Immunopharma, Inc.同业对比
Estrella Immunopharma, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ESLA本股 | $24M#9 | — | — | — | — | — | — | — | — | — | -50.9%#8 | — |
| TIL | $49M#2 | — | 0.5x#2 | — | -100.0%#7 | 3.7%#7 | — | -66.5%#3 | — | — | -66.5%#11 | — |
| SCLX | $46M#3 | — | — | 1.5x#1 | -46.5%#5 | -413.8%#15 | -1143.7%#3 | — | — | 4#1 | -74.0%#12 | — |
| MGX | $42M#4 | — | 0.4x#1 | 1.7x#2 | -51.8%#6 | -12.6%#9 | -380.9%#2 | -78.1%#5 | — | — | -48.0%#6 | — |
| ATYR | $36M#5 | — | 0.7x#4 | 188.7x#5 | -19.1%#3 | -15.8%#10 | -40856.3%#6 | -151.9%#7 | -202.0%#2 | — | -65.0%#10 | — |
| ALGS | — | — | — | — | -39.5%#4 | 81.6%#2 | -4024.9%#4 | -75.9%#4 | — | — | -50.2%#7 | — |
| QNCX | $30M#6 | 0.2x#2 | — | — | — | -47.8%#12 | — | — | — | — | -90.7%#15 | — |
| CVM | $27M#8 | — | 2.5x#6 | 103.9x#4 | 65.5%#1 | 5.6%#6 | -9396.5%#5 | -231.9%#8 | — | — | -82.6%#14 | — |
| GRMLW | $28M#7 | — | 0.5x#3 | — | — | -71.6%#13 | — | -18.2%#2 | -14.6%#1 | — | -33.1%#3 | — |
| JSPR | $21M#10 | — | 14.6x#10 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | -76.1%#13 | — |
| PHGE | $49M#1 | 0.1x#1 | 4.5x#8 | — | — | -104.2%#14 | — | -333.2%#10 | -377.8%#3 | — | -97.9%#16 | — |
| BCDA | $17M#11 | — | 6.3x#9 | — | -100.0%#7 | -3.5%#8 | — | -304.7%#9 | — | — | -27.0%#2 | — |
| DYAI | $16M#12 | — | — | 5.0x#3 | -11.6%#2 | -26.8%#11 | -232.8%#1 | — | — | — | -56.9%#9 | — |
| PASG | $15M#13 | — | 3.4x#7 | — | — | 29.7%#3 | — | -1021.6%#11 | — | — | -34.8%#4 | — |
| BCLI | $13M#14 | — | — | — | — | 11.3%#5 | — | — | — | — | -1.7%#1 | — |
| INTS | $13M#15 | — | 1.4x#5 | — | — | 28.7%#4 | — | -126.0%#6 | — | — | -36.6%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议